|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
12 December 2020 |
|
Main ID: |
NCT02449967 |
|
Date of registration:
|
12/05/2015 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA) for Pancreatic Cancer
|
|
Scientific title:
|
HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA) for Pancreatic Cancer: Clinical Trial |
|
Date of first enrolment:
|
May 2015 |
|
Target sample size:
|
0 |
|
Recruitment status: |
Withdrawn |
|
URL:
|
https://clinicaltrials.gov/show/NCT02449967 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
|
|
Phase:
|
Phase 1/Phase 2
|
|
|
Countries of recruitment
|
|
China
| | | | | | | |
|
Contacts
|
|
Name:
|
Lizhi Liu, PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Fuda Cancer Hospital |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
1. Age:18-80
2. Karnofsky performance status >60
3. Diagnosis of pancreatic cancer based on histology or the current accepted radiological
measures.
4. Classification tumor,nodes,metastasis-classification(TNM) stage: ?,?,?
5. Will receive interventional therapy
6. Life expectancy: Greater than 3 months
7. Patients' routine blood test, liver function and kidney function have no obvious
abnormalities
8. Ability to understand the study protocol and a willingness to sign a written informed
consent document
Exclusion Criteria:
1. Patients with other primary tumor except pancreatic cancer
2. History of coagulation disorders or anemia
Age minimum:
18 Years
Age maximum:
80 Years
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Pancreatic Cancer
|
|
Intervention(s)
|
|
Procedure: interventional therapy
|
|
Primary Outcome(s)
|
|
Number of participants with Adverse events
[Time Frame: 1 year]
|
|
Secondary Outcome(s)
|
|
Progress free disease (PFS)
[Time Frame: 1 year]
|
|
Overall survival (OS)
[Time Frame: 3 year]
|
|
Percentage of lesions that show no sign of recurrence 12 months after interventional therapy
[Time Frame: 1 year]
|
|
Secondary ID(s)
|
|
Pancreatic Cancer HepaSphere
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|